Federated Hermes’s VYNE Therapeutics VYNE Stock Holding History

Federated Hermes’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-127	Closed	-$513	–	2222
2023 Q3	$513	Hold	127	–	–	﹤0.01%	2040
2023 Q2	$521	Hold	127	–	–	﹤0.01%	2055
2023 Q1	$391	Sell	127 -1	-0.8%	-$4	﹤0.01%	2087
2022 Q4	$344	Hold	128	–	–	﹤0.01%	2107
2022 Q3	$1K	Hold	128	–	–	﹤0.01%	2087
2022 Q2	$1K	Hold	128	–	–	﹤0.01%	2091
2022 Q1	$1K	Hold	128	–	–	﹤0.01%	2125
2021 Q4	$2K	Hold	128	–	–	﹤0.01%	2069
2021 Q3	$3K	Buy	+128	New	+$4.96K	﹤0.01%	2075
2019 Q2	–	Sell	-8	Closed	-$4K	–	2228
2019 Q1	$4K	Sell	8 -1	-11%	-$480	﹤0.01%	2009
2018 Q4	$3K	Buy	+9	New	+$4.03K	﹤0.01%	2054

Other funds holding VYNE

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

AlphaCentric Advisors San Juan, Puerto Rico $100M AUM

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

EAM

Exome Asset Management New York $193M AUM 208.51% 1-Year Est. Return

PCM

Prelude Capital Management New York $1.31B AUM 62.01% 1-Year Est. Return

Federated Hermes's VYNE Position: Q4 2023 in Review

Federated Hermes sold out of VYNE Therapeutics (VYNE) in Q4 2023, closing a stake of 127 shares — an estimated $513 sold.

Federated Hermes first reported a position in VYNE in Q4 2018 and held it in 11 quarters. The position peaked at $4K in Q1 2019. 33 funds tracked by Wall St. Rank hold VYNE as of Q4 2023.

Federated Hermes reported no remaining VYNE Therapeutics position as of Q4 2023 after selling out during the quarter.
Federated Hermes sold 127 VYNE Therapeutics shares in Q4 2023, an estimated $513.
Federated Hermes first reported a position in VYNE Therapeutics in Q4 2018 and held it in 11 quarters.
Federated Hermes's VYNE Therapeutics position peaked at $4K in Q1 2019.
33 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2023.

Based on Federated Hermes's 13F filing for Q4 2023, filed 31 Jan 2024.